Medtronic has completed its acquisition of biologic developer Osteotech for $123 million, or $6.50 per share in cash.
Medtronic completes Osteotech acquisition
The deal, first announced in August,
expands Minneapolis-based Medtronic's bone-healing technologies, according to a Medtronic news release.
"The acquisition complements our bone-healing portfolio and will expand our current presence in spine, orthopedic trauma and dental into new treatments areas including joint reconstruction, foot and ankle, sports medicine and neurosurgery," Tom McGuinness, Medtronic's biologics general manger, said in the release. Medtronic's biologics business is headquartered in Memphis, Tenn.
Send us a letter
Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.